title: Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
abstract: The effects of irsogladine (CAS 84504-69-8) on P450-isoform specific activities in human hepatic microsomes were examined. Irsogladine had little effects on coumarin hydroxylation (CYP2A6), 7-benzyloxyresorufin O-debenzylation (CYP2B6), S-mephenytoin hydroxylation (CYP2C19), bufuralol hydroxylation (CYP2D6), chlorzoxazone hydroxylation (CYP2E1) and nifedipine oxidation (CYP3A4) at concentrations ranging from 10 to 50 pmol/L. However, it inhibited 7-ethoxyresorufin O-deethylation (CYP1A2) and tolbutamide hydroxylation (CYP2C9) with the Ki values of 276 and 156 micromol/L, respectively. This suggests that it is a weak inhibitor of these isoforms. Because the plasma concentrations of irsogladine in humans are much lower than these Ki values, it is unlikely that irsogladine causes drug interactions with other drugs.
authors.affiliation: Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Japan. ak.nakamura@po.nippon-shinyaku.co.jp
authors.forename: Akio
authors.initials: A
authors.lastname: Nakamura
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Tougou
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kitazumi
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Yamada
authors.forename: Kumikto
authors.initials: K
authors.lastname: Honjou
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Nonaka
authors.forename: Hideya
authors.initials: H
authors.lastname: Mukai
mesh_terms: D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D065637:Cytochrome P-450 CYP2A6; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000378:metabolism; D007700:Kinetics; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D010089:Oxidoreductases, N-Demethylating / Q000378:metabolism; D014227:Triazines / Q000494:pharmacology*
chemical_list: D000897:Anti-Ulcer Agents; D007527:Isoenzymes; D014227:Triazines; D009249:NADP; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D019392:Cytochrome P-450 CYP2E1; D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; C585599:CYP2B6 protein, human; C045793:CYP2C19 protein, human; D019363:Cytochrome P-450 CYP1A1; D065637:Cytochrome P-450 CYP2A6; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D010089:Oxidoreductases, N-Demethylating; C041836:irsogladine